Metastatic breast cancer trials in Germany

In Germany 53 Also abroad 610

53 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
Where
Berlin, Bochum, Bottrop, Cologne, Dresden, Duesseldorf, Essen, Esslingen am Neckar, Frankfurt/Main, Hamburg, Hanover, Homburg, Hösbach, Kiel, Koblenz, Leipzig, Lübeck, Muenster, Munich, Ravensburg, Velbert, Westerstede
Age
18 years and over
People
233 worldwide
Run by
BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Erlangen, Essen
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Aachen, Aschaffenburg, Bottrop, Dresden, Eggenfelden, Erlangen, Freiburg im Breisgau, Freiburg Im Breisgau, Krefeld, Mannheim, Munich
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Dessau, Essen, Hamburg, Hanover, Heidelberg, Koblenz, Langen, München, Paderborn, Witten, Wuppertal
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Cologne, Dresden, Essen, Halle Saale, Hamburg, Hanover, Heidelberg, Koblenz, Langen (Hessen), Muenster, Potsdam, Regensburg, Saarbruecken, Tuebingen, Ulm
Age
18 years and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Friedrichshafen, Göttingen, Hamburg, Homburg, Leipzig, Ludwigsburg, Mainz, München, Potsdam, Suhl, Wiesbaden, Witten, Wuppertal
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 3Taking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Chemnitz, Detmold, Dortmund, Homburg, Trier, Ulm
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
Phase 2Taking people
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Where
Aachen, Dessau-Rosslau, Duesseldorf, Essen, Heidelberg, Penzberg, Tuebingen
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00
Phase 3Taking people
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
Where
Berlin, Bottrop, Cologne, Dresden, Essen, Muenster, Munich, Ulm
Age
18 years and over
People
264 worldwide
Run by
Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Aachen, Augsburg, Berlin, Dessau-Rosslau, Duesseldorf, Erlangen, Goettingen, Hamburg, Hanover, Heidelberg, Kiel, Leipzig, Ludwigsburg, Muenster, Munich
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 3Taking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Dresden, Munich
Age
18 years and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
Phase 4Taking people
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
Where
Amberg, Aschaffenburg, Augsburg, Bad Nauheim, Bamberg, Bergisch Gladbach, Berlin, Bottrop, Bremen, Celle, Chemnitz, Cologne, Cottbus, Dessau-Rosslau, Dresden, Duesseldorf, Eggenfelden, Elxleben, Erlangen, Essen, Esslingen am Neckar, Eutin, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Fürstenwalde, Fürth, Georgsmarienhuette, Gifhorn, Goettingen, Göttingen, Gummersbach, Günzburg, Halle, Hamburg, Hamm, Hanau, Hanover, Heidelberg, Heilbronn, Homburg, Ilsede, Karlsruhe, Kempten (Allgau), Kiel, Krefeld, Kulmbach, Landshut, Langen (Hessen), Lebach, Leipzig, Lemgo, Lörrach, Magdeburg, Mainz, Marburg, Marktredwitz, Mayen, Minden, Mönchengladbach, Munich, Münster, Neumarkt, Nordhausen, Nuertingen, Nuremberg, Paderborn, Plauen, Potsdam, Ravensburg, Regensburg, Rheine, Rosenheim, Rotenburg (wümme), Ruesselsheim Am Main, Salzwedel, Hansestadt, Scheuditz, Schorndorf, Schweinfurt, Singen (hohentwiel), Soest, Speyer, Stendal, Stralsund, Stuttgart, Torgau, Trier, Troisdorf, Tuebingen, Ulm, Waldkirchen, Weiden I.D.Opf., Weinheim, Wesel, Westerstede, Wiesbaden, Winnenden, Wolfenbüttel, Wuppertal
Age
18 years and over
People
2,000
Run by
Institut Für Frauengesundheit GmbH
See details and how to joinNCT05452213 · EU 2022-500764-35-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Aachen, Essen, Freiburg Im Breisgau, Georgsmarienhuette, Goettingen, Hamburg, Hanover, Heidelberg, Moenchengladbach, Munich, Paderborn
Age
18 years and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in Germany
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 1Taking people
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
Where
Frankfurt Am Main, Ulm
Age
18 years and over
People
40 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522707-26-00 · EU 2025-522707-26-00
Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
Leipzig
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Augsburg, Berlin, Duesseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Magdeburg, Ravensburg, Ulm
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Where
Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier, Velbert
Age
18 years to 130 years
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT07647328
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Amberg, Berlin, Bottrop, Duesseldorf, Erfurt, Erlangen, Freiburg Im Breisgau, Muenster, Munich, Saarbruecken, Ulm
Age
18 years and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Berlin, Düsseldorf, Erlangen, Essen, Georgsmarienhütte, Gera, München, Potsdam, Saarbrücken
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 1/2Taking people
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participants with Breast Cancer
Where
Dresden, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Tuebingen
Age
18 years and over
People
73 worldwide
Run by
Genentech Inc.
See details and how to join2025-521128-31-00 · EU 2025-521128-31-00
Phase 3Taking people
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Where
Duesseldorf, Mainz, Saarbruecken, Wuppertal
Age
18 years and over
People
1,180 worldwide
Run by
Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01
Phase 2Taking people
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2- NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
Where
Berlin, Bottrop, Leipzig, Schwerte
Age
18 years and over
People
25 worldwide
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2026-525328-10-00 · EU 2026-525328-10-00